Progression-free survival is increasingly being used as a primary end point in new oncology drug trials. However, a new analysis questions whether interventions which prolong progression-free survival in cancer patients actually improve their quality of life. To ensure that patients are obtaining important benefit from cancer therapies, we should measure health-related quality of life directly.